Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GCPM-HIPEC: Retlirafusp alfa, nab-paclitaxel, apatinib, and HIPEC in advanced gastric cancer with peritoneal metastasis
NCT07904442Phase 2Not yet recruiting
- Sponsor
- Anhui Provincial Tumor Hospital
- Start
- Nov 2026
- Primary completion
- Dec 2029
01
Overview
A Phase 2 trial of retlirafusp alfa in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Anhui Provincial Tumor Hospital. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
retlirafusp alfa
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07904442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07904442.